EZH2在腹膜透析相关性腹膜纤维化中的研究进展  

Research progress in the role of enhancer of zeste homolog 2(EZH2)in peritoneal dialysis-associated peritoneal fibrosis

作　　者：孙帅 张坤英[2] 赵军[2] SUN Shuai;ZHANG Kun-ying;ZHAO Jun(School of Clinical Medicine,Weifang Medical University,Weifang 261000,China;Department of Nephrology,Weifang People's Hospital,Weifang 261000,China)

机构地区：[1]潍坊医学院临床医学院,潍坊261000 [2]潍坊市人民医院肾内科,潍坊261000

出　　处：《中国血液净化》2023年第7期533-536,共4页Chinese Journal of Blood Purification

摘　　要：zeste基因增强子同源物2(enhancer of zeste homolog 2,EZH2)是一种组蛋白赖氨酸甲基转移酶,可通过调控组蛋白H3在赖氨酸27位点的三甲基化(trimethylation of Lys27 in histone 3,H3K27me3),诱导靶基因沉默,在腹膜透析(peritoneal dialysis,PD)相关性腹膜纤维化过程中发挥重要作用。研究显示EZH2在腹膜纤维化过程中高表达,通过促进上皮细胞—间充质转化(epithelial-to-mesenchymal transition,EMT)、腹膜炎症和血管新生来促进腹膜纤维化的发生发展,抑制EZH2可抑制甚至部分逆转腹膜纤维化。深入研究EZH2有助于进一步明确腹膜纤维化的发病机制,并为腹膜纤维化的靶向治疗提供参考。Enhancer of zeste homolog 2(EZH2)is a histone lysine methyltransferase,which induces the silence of target gene by regulating trimethylation of Lys27 in histone 3(H3K27me3)and plays an important role in peritoneal dialysis-associated peritoneal fibrosis.Studies have shown that EZH2 is highly expressed in the process of peritoneal fibrosis and induces the development of peritoneal fibrosis by promoting epithelial-to-mesenchymal transition(EMT),peritoneal inflammation and angiogenesis.Inhibition of EZH2 can reduce or even partially reverse peritoneal fibrosis.Further study of EZH2 can be helpful to clarify the pathogenesis of peritoneal fibrosis and to find out target treatment for peritoneal fibrosis.

关 键 词：zeste基因增强子同源物2 腹膜透析 腹膜纤维化 

分 类 号：R459.5[医药卫生—治疗学]